Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.49 |
| ▸ | PTGIR | P43119 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8894747 | 1.00 | YTHDC1 (0.49) | YTHDC1PTGIRMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL17802162 | 0.99 | YTHDC1 (0.48) | YTHDC1PTGIRMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8906626 | 0.99 | YTHDC1 (0.48) | YTHDC1PTGIRMEN1KMT2AALDH1A1 | |
| SCHEMBL28722430 | 0.89 | YTHDC1 (0.47) | YTHDC1MEN1KMT2AALDH1A1ACKR3 | |
| SCHEMBL28722431 | 0.89 | YTHDC1 (0.47) | YTHDC1MEN1KMT2AALDH1A1ACKR3 | |
| SCHEMBL17802181 | 0.89 | YTHDC1 (0.47) | YTHDC1MEN1KMT2AALDH1A1ACKR3 | |
| SCHEMBL19328314 | 0.89 | YTHDC1 (0.47) | YTHDC1MEN1KMT2AALDH1A1ACKR3 | |
| SCHEMBL12761893 | 0.87 | YTHDC1 (0.46) | YTHDC1MEN1KMT2AALDH1A1SLC6A2 | |
| SCHEMBL21222203 | 0.87 | YTHDC1 (0.46) | YTHDC1MEN1KMT2AALDH1A1ACKR3 | |
| SCHEMBL21222207 | 0.87 | YTHDC1 (0.46) | YTHDC1MEN1KMT2AALDH1A1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| EP-2922845-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | CD38, NQO1, NADK | YTHDC1 4564/4885PTGIR 1779/4885MEN1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.